Business
Corxel will use the fundraising proceeds to advance the oral GLP-1 therapy CX11 through mid-stage development in the U.S., as well as prepare for its Phase III studies.
FEATURED STORIES
After winning a surprise approval for its hereditary angioedema drug Ekterly, KalVista is confident the oral offering will capture the lion’s share of the market for on-demand use.
Biohaven has suffered a few setbacks in recent months, including an FDA rejection and a missed $150 million benchmark payment, but CEO Vlad Coric looked for the brighter side at JPM, specifically emphasizing a serendipitous discovery that could get the company in the obesity game.
Henry Gosebruch, who has $3.5 billion in capital to deploy, is thinking broad as he steers the decades-old biotech out of years of turmoil.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Plenty to be thankful for this week for these biopharma companies, especially with the influx of cash.
Vaccibody has changed its name to Nykode Therapeutics. “Nykode” means “new code,” which plays on the potential of the company to generate novel codes and innovative patient therapies.
After months of ongoing testimony from various whistleblowers and investors, Elizabeth Holmes, Theranos founder and CEO, has finally taken the witness stand in her fraud trial.
It’s been a busy week so far, with new discovery facilities launched in the biotech space.
ARO-HSD will be evaluated in a Phase I/II trial that will assess the safety, tolerability, pharmacokinetics, and pharmacodynamic effects of its ability to target HSD17B13 as a treatment for NASH.
Twist Bioscience snapped up in vivo antibody discovery company Abveris Inc. in a deal valued at up to $190 million. The acquisition is expected to bolster Twist’s biopharma antibody capabilities.
Under the strategic collaboration, Neurocrine Biosciences and Sosei Group Corporation will develop and commercialize novel muscarinic receptor agonists to treat the said illnesses.
CStone forged a licensing agreement with Jiangsu Hengrui Pharmaceuticals that grants the company access to a monoclonal antibody aimed at multiple forms of cancer.
“I hope to thread the needle between pricing responsibly and achieving profitability,” Jarrett said.
A Chinese professor at the University of Copenhagen in Denmark is under scrutiny over undisclosed ties to the Chinese military.